Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage
Prothena’s lead drug has decisively failed a crucial Phase IIb study for rare, second-line cases of AL amyloidosis. And after concluding that their Phase III for frontline use is also headed to failure, the biotech’s executive team is scrapping the whole program.
In a preview of the results being released this morning for one of the most closely watched catalysts of Q2, Prothena $PRTA CEO Gene Kinney said the company faced a very difficult decision, and had only one real option.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.